NEWS
Clearside Biomedical Announces Completion of Final Participant Visit in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD
Clearside Biomedical (Nasdaq: CLSD) has announced the completion of the final participant visit in its ODYSSEY Phase 2b clinical trial of CLS-AX for wet AMD. CLS-AX is a highly potent tyrosine kinase inhibitor delivered suprachoroidally using Clearside's proprietary SCS Microinjector®. The company expects to report topline data during the week of October 7, 2024.
The ODYSSEY trial represents a significant milestone for Clearside, with the potential to offer a safer treatment option and reduced treatment burden for wet AMD patients. The company believes there is a compelling market opportunity for CLS-AX, combining the highly-potent TKI axitinib with suprachoroidal delivery. Clearside plans to present the data at events preceding the annual American Academy of Ophthalmology meeting in Chicago.
The ODYSSEY trial represents a significant milestone for Clearside, with the potential to offer a safer treatment option and reduced treatment burden for wet AMD patients. The company believes there is a compelling market opportunity for CLS-AX, combining the highly-potent TKI axitinib with suprachoroidal delivery. Clearside plans to present the data at events preceding the annual American Academy of Ophthalmology meeting in Chicago.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
1281Followers
77Following
9045Visitors
Follow